Skip to main content

H2-Receptor Antagonists: Development and Application

Buy Article:

$39.50 plus tax (Refund Policy)


The advent of H2-receptor antagonists has dramatically advanced the understanding and treatment of peptic ulcer disease. Ranitidine and cimetidine have been shown to be safe and effective in healing duodenal and gastric ulcers and in prevention of duodenal ulcer relapse. Due to differences in chemical structure, ranitidine is more potent and has a longer duration of action and fewer side effects than cimetidine. The current trend in therapy is toward less frequent dosing patterns with more attention toward controlling nocturnal acid secretion. Possibilities for other therapeutic uses of H2-receptor antagonists are suggested.

Document Type: Research Article


Publication date: July 1, 1986

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more